Inovio Pharmaceuticals

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, Merck, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative

Blue Bell, US
Size (employees)
157 (est)
Inovio Pharmaceuticals is headquartered in Blue Bell, US

Key People/Management at Inovio Pharmaceuticals

J. Joseph Kim

J. Joseph Kim


Inovio Pharmaceuticals Office Locations

Inovio Pharmaceuticals has an office in Blue Bell
Blue Bell, US (HQ)
1787 Sentry Parkway West

Inovio Pharmaceuticals Financials and Metrics

Inovio Pharmaceuticals Financials

Inovio Pharmaceuticals's revenue was reported to be $8.5 m in FY, 2016

Revenue (Q2, 2017)

20.4 m

EBIT (Q2, 2017)

(9.6 m)

Market capitalization (13-Nov-2017)

396.3 m

Cash (30-Jun-2017)

23.9 m
Inovio Pharmaceuticals's current market capitalization is $396.3 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


13.5 m10.5 m40.6 m8.5 m

Revenue growth, %



(19.5 m)(39.5 m)(34.3 m)(22.4 m)

EBIT margin, %

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


9.5 m2.4 m3.8 m1.8 m5.2 m5.3 m24.2 m8.1 m6.2 m12.5 m10.4 m20.4 m

R&D expense

5.4 m8.2 m9.6 m7 m9.4 m16.7 m16.1 m18.2 m19.6 m27 m24.5 m23.9 m

General and administrative expense

3.3 m4.1 m4.3 m3.2 m4.1 m4.7 m4.4 m5.4 m5.8 m5.8 m7.8 m6.2 m

Operating expense total

8.7 m12.4 m14 m10.2 m13.5 m20.4 m20.5 m23.6 m24.4 m32.7 m32.3 m30 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


33.7 m40.5 m57.6 m19.1 m

Accounts Receivable

3.3 m2.8 m7.3 m15.8 m


637.4 k798 k917.3 k1.7 m

Current Assets

58.7 m98.9 m171.9 m124.6 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017


33.1 m98.8 m88.5 m70.7 m26.1 m70.3 m85.5 m41.6 m28.5 m23.3 m22.9 m23.9 m

Accounts Receivable

10.6 m2.7 m2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m7.5 m

Current Assets

57.9 m121.7 m112.9 m104.6 m87.3 m162.1 m184.1 m160.6 m148 m140.2 m106.8 m106.9 m


10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.1 m10.5 m10.5 m10.5 m10.5 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.1 m)(36.1 m)(29.1 m)(73.7 m)

Depreciation and Amortization

2.1 m1.6 m1.9 m3.1 m

Accounts Receivable

(2.5 m)499.2 k(4.5 m)(8.5 m)


(229.7 k)(160.5 k)(119.3 k)(831.8 k)
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(30.9 m)(10.8 m)(10.7 m)(7.2 m)(10.6 m)(6.2 m)5.6 m(8 m)(18.7 m)(20.8 m)

Accounts Receivable

2.9 m1.6 m3.3 m5.6 m11 m11.2 m10.4 m17.5 m9.9 m

Accounts Payable

5.3 m4.7 m4.4 m6.1 m10.5 m12.1 m12.7 m16.2 m14.5 m
Y, 2017

Financial Leverage

1.3 x
Show all financial metrics

Inovio Pharmaceuticals Operating Metrics

FY, 2016

Patents Issued

Show all operating metrics

Inovio Pharmaceuticals Market Value History

Inovio Pharmaceuticals's Web-traffic and Trends

Inovio Pharmaceuticals Online and Social Media Presence

Inovio Pharmaceuticals Company Life and Culture

You may also be interested in